drugset / Trial / NCT07136142

A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

NCT07136142

Phase 1/2 Not yet recruiting 150 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.

Timeline

Start
2025-08
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FH-006 Unknown

Indications